Modified Chemotherapy Regimen Effective in Advanced Ovarian Cancer
Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers report in The Lancet Oncology. In a large phase III clinical trial, women who received carboplatin and a reduced dose of paclitaxel (Taxol®) instead of carboplatin and a higher single dose of paclitaxel had a 29 percent improvement in progression- free survival and a 25 percent improvement in overall survival.
Although the toxicities of this dose-dense regimen were greater than they were in women who received the standard combination, survival benefits of this magnitude “have been rare in women with advanced ovarian cancer,” write Dr. Noriyuki Katsumata and colleagues.
♦ ♦ ♦ ♦ ♦
This article was originally published in Coping® with Cancer magazine, November/December 2009.